You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Treating Obesity Today: Effective Discussions With Your Patients

  • Authors: Robert F. Kushner, MD; Caroline Apovian, MD  
  • CME Released: 9/15/2014
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 9/15/2015
Start Activity


Target Audience and Goal Statement

This activity is intended for primary care clinicians, endocrinologists, diabetologists, and other allied healthcare professionals who manage patients who are obese.

The goal of this activity is to focus on the global public health crisis of obesity and to demonstrate how motivational interview techniques can be used by clinicians to help patients who are overweight or obese establish a partnership with their clinician and foster patient adherence to an individualized weight loss management plan.

Upon completion of this activity, participants will be able to:

  1. Identify health consequences of untreated obesity and its association with the development and progression of comorbidities
  2. Translate techniques of motivational interviewing to increase provider-patient discussions regarding obesity management


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Robert F. Kushner, MD

    Professor of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois

    Disclosures

    Disclosure: Robert F. Kushner, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Eisai Inc.; Novo Nordisk; Takeda Pharmaceuticals North America Inc.; VIVUS Inc.
    Received grants for clinical research from: Aspire Bariatrics; Weight Watchers

    Dr Kushner does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Kushner does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist

  • Caroline Apovian, MD

    Director, Nutrition and Weight Management; Professor of Medicine and Pediatrics, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts

    Disclosures

    Disclosure: Caroline Apovian, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amylin Pharmaceuticals, Inc.; Arena Pharmaceuticals, Inc.; EnteroMedics; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck & Co., Inc.; Nutrisystem, Inc.; Orexigen Therapeutics, Inc.; Sanofi; Zafgen
    Received grants for clinical research from: Amylin Pharmaceuticals, Inc.; Aspire Bariatrics, Inc.; Endo Barrier (GI Dynamics); Lilly; MetaProteomics; Orexigen Therapeutics, Inc.; Pfizer Inc; Dr. Robert C. and Veronica Atkins Foundation; Sanofi

    Dr Apovian does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Apovian does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

  • Anne G. Le, PharmD, RPh

    Lead Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Anne G. Le, PharmD, RPh, has disclosed no relevant financial relationships.

  • Eve J. Wilson, PhD, CCMEP

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Eve J. Wilson, PhD, CCMEP, has disclosed no relevant financial relationships.

Steering Committee

  • Ken Fujioka, MD

    Director, Nutrition and Metabolic Research Center, Scripps Clinic, La Jolla, California

    Disclosures

    Disclosure: Ken Fujioka, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Orexigen Therapeutics, Inc.; Novo Nordisk; Enteromedics, Inc.; Zafgen; NPS Pharmaceuticals, Inc.; Eisai, Inc.; NaZura BioHealth, Inc.; Pathway Genomics Corporation; Isis Pharmaceuticals, Inc.
    Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; NPS Pharmaceuticals, Inc.; Eisai, Inc.; VIVUS Inc.
    Received grants for clinical research from: Orexigen Therapeutics, Inc.; Novo Nordisk; Enteromedics, Inc.; Shire, NPS Pharmaceuticals, Inc.; Eisai, Inc.; Weight Watchers

  • Timothy Church, MD, MPH, PhD

    Professor, Pennington Biomedical Research Center, Baton Rouge, Louisiana

    Disclosures

    Disclosure: Timothy Church, MD, MPH, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: VIVUS Inc.
    Received grants for clinical research from: VIVUS Inc.; Coca Cola; Orexigen Therapeutics, Inc.; Arena Pharmaceuticals, Inc.
    Owns stocks, stocks options, or bonds from: Catapult Health; FIX: Fitness Interactive eXperience
    Employed by a commercial interest: ACAP Health

  • Timothy Garvey, MD

    Butterworth Professor and Chair, Department of Nutrition Sciences, University of Alabama at Birmingham; Director, University of Alabama at Birmingham Diabetes Research Center; Investigator and Staff Physician, Geriatric Research, Education, and Clinical Center, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama

    Disclosures

    Disclosure: Timothy Garvey, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Daiichi Sankyo, Inc.; VIVUS Inc.; Eisai, Inc.; Takeda Pharmaceuticals North America, Inc.; Novo Nordisk; Janssen Pharmaceuticals, Inc.; LipoScience Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Merck & Co., Inc.; Weight Watchers; Sanofi; Eisai, Inc.
    Owns stocks, stocks options, or bonds from: Pfizer, Inc.; Lilly; Merck & Co., Inc.; Isis Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation

  • Patrick O'Neil, PhD

    Director, Weight Management Center; Professor, Department of Psychiatry and Behavioral Sciences; Professor, Department of Surgery, Medical University of South Carolina, Charleston, South Carolina

    Disclosures

    Disclosure: Patrick O'Neil, PhD, has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: Eisai Inc.; Novo Nordisk
    Received grants for clinical research from: Orexigen Therapeutics, Inc.; Weight Watchers; Novo Nordisk
    Received reimbursement for travel expenses from: VIVUS, Inc.

  • Donna Ryan, MD

    Professor Emeritus, Bennington Biomedical Research Center, Baton Rouge, Louisiana

    Disclosures

    Disclosure: Donna Ryan, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Novo Nordisk; Eisai, Inc.; Takeda Pharmaceuticals North America, Inc.; VIVUS Inc.; Janssen Pharmaceuticals, Inc.
    Served as a speaker or a member of a speakers bureau for: Takeda Pharmaceuticals North America, Inc.
    Owns stocks, stocks options, or bonds from: Scientific Intake

  • Steven R. Smith, MD

    Professor, Sanford-Burnham Medical Research Institute; Chief Scientific Officer/Senior Vice President, Florida Hospital; Scientific Director, Translational Research Institute for Metabolism and Diabetes, Orlando, Florida

    Disclosures

    Disclosure: Steven R. Smith, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amylin Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Arena Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals Inc.; Bristol Meyers Squibb Company; Eisai, Inc.; Elcelyx Therapeutics, Inc.; Lilly; FivePrime Therapeutics; GlaxoSmithKline; NGM Biopharmaceuticals, Inc.; Novo Nordisk; Orexigen Therapeutics, Inc.; Piramal Life Sciences; Takeda Pharmaceuticals North America, Inc.; Zafgen
    Received grants for clinical research from: Amylin Pharmaceuticals, Inc.; Lilly; Takeda Pharmaceuticals North America, Inc.
    Owns stocks, stocks options, or bonds from: Jenrin Discovery Inc; Zafgen

CME Reviewer(s)

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Treating Obesity Today: Effective Discussions With Your Patients

Authors: Robert F. Kushner, MD; Caroline Apovian, MD  Faculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 9/15/2014

Valid for credit through: 9/15/2015

processing....

Welcome and Introductions

  • Robert F Kushner, MD: Hello. I am Dr Robert Kushner, clinical director at Northwestern Comprehensive Center on Obesity and professor of medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. Welcome to this program, in which we discuss the global public health crisis of obesity and strategies to develop a partnership to promote weight loss with patients who are overweight or obese.

    Joining me today is my good friend and colleague, Dr Caroline Apovian, who is professor of medicine and pediatrics in the Department of Medicine at the Boston University School of Medicine and director of the Nutrition and Weight Management Center at Boston Medical Center in Massachusetts.

    Welcome, Caroline.

    Caroline M. Apovian, MD: It is a pleasure to be here, Bob.

    Dr Kushner: The goals for this program are to identify health consequences of untreated obesity and its association with the development and progression of comorbidities, and to implement strategies such as motivational interviewing to discuss obesity, its comorbidities, and treatment options more effectively, moving toward developing therapeutic partnerships with patients.

    Before I begin my discussion, please take a moment to test your knowledge on this topic by answering a few questions. You will have another chance to answer these questions at the end of the activity to see what you have learned.

  • Slide 1.

    Slide 1.

    (Enlarge Slide)

Educational Impact Challenge

Assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print